ArticleScience advances2021
INSIGHT: A population-scale COVID-19 testing strategy combining point-of-care diagnosis with centralized high-throughput sequencing.
Article in Science advances, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed.
- Recognition, Signal Transduction, and Amplification of Nucleic Acids Under Isothermal Condition.Advanced genetics (Hoboken, N.J.) · 2026Article
- A One-Pot RT-LAMP Diagnostic Assay for SARS-CoV‑2 from Saliva Samples.ACS measurement science au · 2025Article
- Leveraging Deep Learning to Address Diagnostic Challenges with Insufficient Image Data.ACS sensors · 2025Article
- Detection of TuMV by a toehold switch sensor coupled with NASBA amplification in Pseudostellaria heterophylla.Plant methods · 2025Article
- A Highly Sensitive and Selective DAMP Assay for the Detection of Bacterial Pathogens Associated With Brain Inflammation.Bio-protocol · 2025Article
- Reaction Pathway Differentiation Enabled Fingerprinting Signal for Single Nucleotide Variant Detection.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Developing, Characterizing, and Modeling CRISPR-Based Point-of-Use Pathogen Diagnostics.ACS synthetic biology · 2025Article
- Preamplification-free viral RNA diagnostics with single-nucleotide resolution using MARVE, an origami paper-based colorimetric nucleic acid test.Nature protocols · 2024Review
- Harnessing the power of clustered regularly interspaced short palindromic repeats (CRISPR) based microfluidics for next-generation molecular diagnostics.Molecular biology reports · 2024Review
- A DAMP-Based Assay for Rapid and Affordable Diagnosis of Bacterial Meningitis Agents:International journal of molecular sciences · 2024Article
- SARS-CoV-2 genomic surveillance of migrants arriving to Europe through the Mediterranean routes.Journal of global health · 2024Article
- Developing, characterizing and modeling CRISPR-based point-of-use pathogen diagnostics.bioRxiv : the preprint server for biology · 2024Article
- DNA-directed formation of plasmonic core-satellite nanostructures for quantification of hepatitis C viral RNA.Chemical science · 2024Article
- Lateral flow assay: a promising rapid point-of-care testing tool for infections and non-communicable diseases.Asian biomedicine : research, reviews and news · 2023Review
- Review
- Evaluation of real-time NASBA assay for the detection of SARS-CoV-2 compared with real-time PCR.Irish journal of medical science · 2023Article
- Research progress of severe acute respiratory syndrome coronavirus 2 on aerosol collection and detection.Chinese chemical letters = Zhongguo hua xue kuai bao · 2023Review
- DNA Nanomachine (DNM) Biplex Assay for DifferentiatingInternational journal of molecular sciences · 2023Article
- Microfluidics for COVID-19: From Current Work to Future Perspective.Biosensors · 2023Review
- Molecular Mechanisms Underlying CRISPR/Cas-Based Assays for Nucleic Acid Detection.Current issues in molecular biology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
We present INSIGHT [isothermal NASBA (nucleic acid sequence-based amplification) sequencing-based high-throughput test], a two-stage coronavirus disease 2019 testing strategy, using a barcoded isothermal NASBA reaction. It combines point-of-care diagnosis with next-generation sequencing, aiming to achieve population-scale testing. Stage 1 allows a quick decentralized readout for early isolation of presymptomatic or asymptomatic patients. It gives results within 1 to 2 hours, using either fluorescence detection or a lateral flow readout, while simultaneously incorporating sample-specific barcodes. The same reaction products from potentially hundreds of thousands of samples can then be pooled and used in a highly multiplexed sequencing-based assay in stage 2. This second stage confirms the near-patient testing results and facilitates centralized data collection. The 95% limit of detection is <50 copies of viral RNA per reaction. INSIGHT is suitable for further development into a rapid home-based, point-of-care assay and is potentially scalable to the population level.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.